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Abstract
Background: A significant barrier to organ transplantation is the cellular rejection that occurs and mediated by
antibodies, T cells, and innate immune cells. This study was aimed to determine the number of CD4+CD25+Foxp3+ Treg,
CD4+IFN-γ−IL-17+ Th17, CD4+IFN-γ+IL-17− Th1 and CD4+IFN-γ+IL-17+ Th1/17 cells in renal transplant recipients (RTR).
Methods: Renal transplantation was performed for a total of 35 patients with end-stage renal failure. The number of
CD4+CD25+Foxp3+ Treg, CD4+IFN-γ−IL-17+ Th17, CD4+IFN-γ+IL-17− Th1 and CD4+IFN-γ+IL-17+ Th1/17 cells, and the
serum level of IFN-γ, TNF-α, IL-2, IL-4, IL-6, IL-10, and IL-17 were measured in pre- and post-transplant patients and 10
healthy controls (HC) using flow cytometry and Cytometric Bead Array (CBA). The association between the number of
different subsets of CD4+ T-cells and clinical parameters were analyzed among the pre- and post-transplant patients,
and the healthy controls.
Results: The number of CD4+IFN-γ−IL-17+ Th17, CD4+IFN-γ+IL-17− Th1 and CD4+IFN-γ+IL-17+ Th1/17
cells were significantly increased in patients with End-Stage Renal Failure (ESRF) compared to the HC.
Stratification analysis indicated that AMR (Acute antibody mediated acute rejection), AR (acute rejection) and
CR (chronic rejection) groups displayed greater number of CD4+IFN-γ−IL-17+ Th17, CD4+IFN-γ+IL-17− Th1 and
CD4+IFN-γ+IL-17+ Th1/17 cells as well as high level of serum IL-2, IFN-γ, TNF-α and IL-17. But, the AMR, AR and
CR groups have shown lower level of CD4+CD25+Foxp3+ T cells and serum IL-10 compared to transplant
stable (TS) patients. Moreover, the number of Tregs were negatively correlated with the number of Th17 cells
in RTR patients. The number of Tregs and Th17 cells were positively correlated with the eGFR and serum
creatinine values, respectively.
Conclusion: The imbalance between different types of CD4+ T cells and dysregulated inflammatory cytokines
may contribute towards renal transplantation rejection.
Background
Renal transplantation is used to improve survival and
quality of life for patients with end-stage renal disease.
In the past, patients often eventually die from complica-
tions [1, 2] if toxins cannot be removed from the body
by hemodialysis. Although renal transplantation is rec-
ognized as the gold strategy for treating renal failure, it
has several limitations including donor’s immune
rejection. In order to identify a means of controlling im-
mune rejection, further illustration on the mechanism
of immune rejection in renal transplant recipients
(RTR) has great significance.
It is generally accepted that a significant barrier to organ
transplantation is the humoral and cellular rejection that
can occur and mediated by antibodies, T cells, and innate
immune cells. Cellular immune response play’s an equally
important role with humoral immune response in allograft
rejection [3, 4]. For instance, there is evidence that a
disturbed T-cell homeostasis play’s a critical role in the
development of acute graft rejection episodes. The main T
subsets which are pivotal for this T-cell balance consists of
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T-helper 17 (Th17) cells and regulatory T (Treg) cells
[5–7]. In addition to well characterized Th1 and Th2
lymphocytes, additional subsets called Th17 cells, which
selectively produce IL-17, have joined the effector CD4+ T
cell lineage. Imbalanced Th17 and impaired Treg cells
have suggested to be involved in the pathogenesis of
allograft rejection, such as heart and lung transplantations
[8–11]. Previous studies have suggested that Th17 cells
are important for clearance of a variety of pathogens and
are associated with numerous autoimmune and inflamma-
tory conditions [12]. In addition, Th17 cells have also been
implicated in acute and chronic rejection in animal
models of allograft transplant [13–16]. Interestingly, the
function of self-reacting effector Th17 cells is controlled by
Tregs, yet another subpopulation of CD4+ T lymphocytes
which express transcription factor FoxP3 [17]. Tregs are
important regulators of immune tolerance and can actively
suppress pro-inflammatory T cell responses [18, 19].
Quantitative and/or qualitative deficiencies of Tregs have
been associated with the development of organ transplant-
ation rejection [20–23]. Previous studies in animal models
have shown that a deficiency in Tregs favors kidney
transplantation rejection [20, 21], though their mechanism
in clinical studies remains unclear. Human Tregs are not as
well characterized as their murine counterparts; in part this
is due to restrictions and limitations of clinical studies.
Furthermore, the characterization of Tregs in humans is
more complex [24, 25]. Human Tregs are CD4+CD25+ and
their development and function depends on the forkhead
family transcription factor (Foxp3) expression [26–28].
Recent study has shown that a lower frequency of circulat-
ing CD4+CD25+Foxp3+ T cells was detected in RTR
patients, and the percentages of CD4+CD25+Foxp3+ T cells
were negatively associated with eGFR of RTR [29].
However, little is known about the number of Tregs and
Th17 cells, and their association with different types of
rejection in RTR patients.
In addition, studies have shown that some inflamma-
tory cytokines, such as Th1-type cytokine (IFN-γ) and
Th17-type cytokine (IL-17), are also associated with
the development of rejection [30–33]. For instance,
IFN-γ can mediate separate functions at the same
target organ during Graft-versus-host disease (GVHD),
and IL-17 can induce the expression of proinflammatory
tumor necrosis factor (TNF)-α, chemotactic protein
(MCP)-1 and macrophage inflammatory protein (MIP)-1
to promote tissue inflammation [30–32]. Furthermore,
IL-17 can also promote the differentiation and matur-
ation of dendritic precursor cells, increased cell
surface expression of CD80, CD40 and major histo-
compatibility complex (MHC)-II antigen [33]. How-
ever, the role of these inflammatory cytokines in
different types of renal transplantation rejection has
not been clarified.
In the current study, we characterized the number of
circulating CD4+CD25+Foxp3+ Tregs and Th17 cells, and
the concentration of serum inflammatory cytokines in dif-
ferent RTR patients and HCs to determine their potential
association with clinical measures in the patients.
Methods
Subjects
A total of 35 patients (20 male and 15 female), 31–48
years of age (median age 38), with an end-stage renal
failure (ESRF) waiting for renal transplantation were
recruited from the inpatient service of the First Hospital
of Jilin University, Changchun, China. Ten gender, ethni-
city and age-matched HCs were included in the study.
Individual patients with ESRF were diagnosed according
to the criteria [34]. Individual patients were treated with
conventional immunosuppressors (Cyclosporine, azathi-
oprine or mycophenolate mofetil and/or steroids) twice
a day for three days. All patients had compatible HLA-
gene matches and the number of those patients who had
HLA (A, B, DR) mismatches were less than two. Individuals
were excluded if she/he had a history of previous renal
transplantation or surgical procedure. Written informed
consent was obtained from individual participants. The ex-
perimental protocol was established according to the guide-
lines of the 1975 Declaration of Helsinki and approved by
the Human Ethics Committee of Jilin University, China.
Study groups
Transplant patients were divided into four groups accord-
ing to graft function (based on estimated glomerular filtra-
tion rate (eGFR) or serum creatinine level) and post-
transplant rejection time (after 12 weeks) as well as the
Banff Classification [35]. The four groups included were:
(a) Transplant Stable (TS) (n = 13): Recipients with stable
graft function under conventional immunosuppressors
(Cyclosporine, azathioprine or mycophenolate mofetil
and/or steroids) and without clinical and laboratory
features suggestive of rejection (serum creatinine level: <
150 umol/L; eGFR: ≥ 50) in 12 weeks; There was no
biopsies of these individuals because they have normal
and stable graft function; (b) Acute antibody mediated
acute rejection (AMR) (n = 8): Recipients under conven-
tional immunosuppressors with clinical symptoms (fever,
graft pain, oliguria or anuria) and progressive renal func-
tion deterioration (serum creatinine level: ≥ 150 umol/L;
eGFR: < 50) during 1 week; The rejection of these individ-
uals was confirmed by biopsy according to Banff criteria;
(c) Acute rejection (AR) (n = 7): Recipients under conven-
tional immunosuppressors with clinical symptoms (fever,
graft pain, oliguria or anuria) and progressive renal func-
tion deterioration (serum creatinine level: ≥ 150 umol/L;
eGFR: < 50) during 2 to 12 weeks; The rejection of these
individuals was confirmed by biopsy according to Banff
Ma et al. BMC Immunology  (2015) 16:56 Page 2 of 12
criteria; (d) Chronic rejection (CR) (n = 7): Recipients under
conventional immunosuppressors with clinical symptoms
(fever, graft pain, oliguria or anuria) and progressive renal
function deterioration (serum creatinine level: ≥ 150 umol/
L; eGFR: < 50) after 12 weeks; The rejection of these indi-
viduals was confirmed by biopsy according to Banff criteria.
These group of patients who received kidney transplant
had no post-transplant malignancy and infective complica-
tions. In case of rejection response, patients withdrew from
the follow-up and receive additional anti-rejection treat-
ment, such as methyl prednisolone, anti-thymocyte globu-
lin or anti-CD3 monoclonal antibody as well as plasma
exchange.
Clinical measurement
Peripheral venous blood samples were obtained from indi-
vidual participants for laboratory test before and after trans-
plant, when rejection-related clinical symptoms appeared.
The routine laboratory investigations include complete
blood count, serum creatinine, BUN and glomerular filtra-
tion rate (eGFR). The laboratory investigations were con-
ducted by scattered turbidimetry using Siemens special
protein analyzer (Siemens Healthcare Diagnostics Products,
GmbH, Germany).
Isolation and stimulation of PBMCs
Peripheral venous blood samples were collected after over-
night fasting. Peripheral blood mononuclear cells (PBMCs)
were isolated by density-gradient centrifugation using
Ficoll-Paque Plus (Amersham Biosciences, Little Chalfont,
UK). PBMCs (106/mL) were stimulated in duplicate with
50 ng/mL of phorbol myristate acetate (PMA) and 1.0 mg/
mL of ionomycin (Sigma, St. Louis, MO, USA) in 10 %
human AB type sera in RPMI 1640 medium at room
temperature in a humidified incubator with 95 % air and
5 % carbon dioxide for 2 h and then cultured for another
4 h in the presence of 0.5 mg/mL of brefeldin A (BFA,
Sigma). The control PBMCs were cultured in medium
alone.
Flow cytometry analysis
The frequency of CD4+IFN-γ+IL-17− Th1, CD4+IFN-γ−IL-
17+ Th17, CD4+IFN-γ+IL-17+ Th1/17 and CD4+CD25
+Foxp3+ T cells in individual samples were determined by
flow cytometry following intracellular staining with anti-
cytokine antibodies. Briefly, the stimulated PBMCs were
harvested and stained with allophycocyanin (APC)-la-
beled anti-CD4, fixed with the Perm/Fix solution, and
permeabilized, followed by staining with fluorescein
isothiocyanate (FITC)-labeled anti–IL-17 and PE-Cy7-
labeled anti-IFN-γ (Becton Dickinson, San Diego,
USA). Additional cells were stained in duplicate with
PerCP-anti-CD4/FITC-anti-CD25 or isotype-matched
controls (BD PharMingen, San Diego, USA) for 30 min,
fixed, and permeabilized using the permeabilization so-
lution (BD Biosciences), followed by intracellular stain-
ing with PE-anti-Poxp-3 (BD PharMingen, San Diego,
USA). After being washed with PBS, these cells were
analyzed on a FACSCalibur (BD Biosciences, San Jose,
USA) and at least 20,000 events were analyzed by
FlowJo software (v7.6.2).
Cytometric bead array for the level of serum cytokines
The concentrations of serum IFN-γ, TNF-α, IL-2, IL-4, IL-
6, IL-10 and IL-17 were determined by cytometric bead
array (CBA), according to the manufacturer’s protocol
(CBA, BD Biosciences) with minor modification. Briefly,
50 μL serum samples were subjected to analysis in dupli-
cate using the cytometric bead array kit on a FACSCalibur
cytometry. The concentration of serum cytokines were
quantified using CellQuestPro and CBA software (Becton
Dickinson). The detection limit for IFN-γ, TNF-α, IL-2,
IL-4, IL-6, IL-10 and IL-17 were 4.1 pg/ml, 3.7 pg/ml,
2.9 pg/ml, 3.3 pg/ml, 2.5 pg/ml, 3.3 pg/ml, and 4.2 pg/ml,
respectively.
Statistical analysis
Data were expressed as median and range for each group
unless specified. The difference between groups was ana-
lyzed by the Kruskal-Wallis test or Chi-square test using
SPSS 16.0 software for unpaired and paired comparisons,
respectively. The relationship between variables was evalu-
ated using the Spearman rank correlation test. A two-side P
value < 0.05 was considered statistically significant.
Results
Patient sociodemographic and clinical characteristics
The sociodemographic and clinical characteristics of RTR’s
are summarized in Table 1. The patients displayed higher
concentration of serum creatinine and BUN and lower level
of eGFR. Furthermore, significantly higher levels of white
blood cell (WBC), and lower levels of red blood cell (RBC)
and hemoglobin (Hb) were detected in ESRF, compared to
the HCs.
RTR’s were divided into four groups according to
graft function (based on eGFR or serum creatinine
level) and post-transplant rejection time (Table 2). TS
Patients showed a significant reduction in BUN and Cr
levels and a significant increase in eGFR values and Hb
compared to the pre transplant status. In addition, the
concentration of serum Cr and BUN in AMR, AR and
CR groups were significantly higher than TS ESRF
patients.
CD4+IFN-γ−IL-17+ Th17, CD4+IFN-γ+IL-17− Th1 and
CD4+IFN-γ+IL-17+ Th1/17 T cells in the patients
The circulating CD4+ T cells analysis (Fig. 1a-g) found
that, the number of CD4+, CD4+IFN-γ−IL-17+ Th17,
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CD4+IFN-γ+IL-17− Th1 and CD4+IFN-γ+IL-17+ Th1/17
cells (Fig. 1a, d-f) in patients with ESRF were significantly
greater than the HCs. In contrast, there was no significant
difference in the number of CD4+CD25+Foxp3+ T cells
(Fig. 1b) between the ESRF patients and HCs. As a result,
the ratio of CD4+CD25+Foxp3+ T cells to CD4+IFN-γ−IL-
17+ Th17 cells (Fig. 1g) was significantly lower in
ESRF patients compared to the HCs. Furthermore,
there was no significant difference in the ratio of
CD4+CD25+Foxp3+ T cells to CD4+IFN-γ+IL-17− Th1
or CD4+IFN-γ+IL-17+ Th1/17 cells between ESRF pa-
tients and the HCs.
The number of CD4 + IFN-γ-IL-17+ Th17, CD4 + IFN-γ + IL-
17- Th1, CD4 + IFN-γ + IL-17+ Th1/17 T and CD4 + CD25 +
Foxp3+ T cells
Further comparison of different types of CD4+ T cells
(Fig. 2a-g) found that, in post-transplant TS patients, the
number of CD4+CD25+Foxp3+ T cells and the ratio of
Tregs to Th17 were significantly increased (Fig. 2c, g),
whereas the number of CD4+, CD4+IFN-γ−IL-17+ Th17,
CD4+IFN-γ+IL-17− Th1 and CD4+IFN-γ+IL-17+ Th1/17
cells were significantly decreased compared to the pre-
transplant status. (Fig. 2b, d-f). Conversely, in the AMR,
AR and CR patients, the number of CD4+CD25+Foxp3+ T
cells is decreased while the numbers of CD4+IFN-γ−IL-17+
Th17, CD4+IFN-γ+IL-17− Th1 and CD4+IFN-γ+IL-17+
Th1/17 cells are increased (Fig. 2b-g). Moreover, there was
no significant change in the ratio of Tregs to Th1 cells in
the pre- and post-transplant status. Interestingly, AMR
patients displayed higher number of CD4+, CD4+IFN-γ−IL-
17+ Th17, CD4+IFN-γ+IL-17− Th1 and CD4+IFN-γ+IL-17+
Th1/17 cells and lower number of CD4+CD25+Foxp3+ T
cells compared to AR and CR patients. These data sug-
gested that altered CD4 + T cells number may be associated
with renal transplantation rejection.
Serum Th1- and Th17-type cytokines in RTR patients
The concentration of serum IL-2, IFN-γ, TNF-α, IL-4,
IL-6, IL-10 and IL-17 in ESRF patients were significantly
increased compared to the HC’s (Fig. 3a). The serum cy-
tokines level were determined and found significantly in-
creased serum levels of IL-2, IFN-γ, TNF-α and IL-17 in
post-transplant TS’s compared to the pre-transplant pa-
tients. TS patients showed an increased level of serum
IL-10 compared to the pre-transplant RTR’s (Fig. 3b).
However, there was no significant difference in the
Table 1 The demographic and clinical characteristics of subjects
Parameters HC ESRF
Number 10 35
Age (years) 37 (30–45) 38 (31–48)
F/M (n) 4/6 15/20
BUN (mmol/L) 4.4 (3.5–7.0) 16.8 (7.2–32.8) *
Cr (umol/L) 88 (65–112) 832 (499–1790) *
eGFR (ml/min) 115 (98–124) 21 (8–67) *
WBC (×109/L) 7.7 (3.6–9.4) 10.9 (8.5–13.9)*
PBMCs (×109/L) 2.7 (0.9–4.5) 2.1 (1.1–3.3) *
RBC (×1012/L) 4.0 (3.7–4.6) 2.4 (1.7–3.1)
Hb (g/L) 128 (111–147) 85 (66–107)
Data shown are median (range) of each group of subjects
ESRF End-stage renal failure, BUN Blood urea nitrogen (normal range:
3.2 ~ 6.0 mmol/L), Cr Serum creatinine (normal ranges: men: 44-133umol/L;
women: 70-108umol/L), eGFR Glomerular filtration rate (normal value: 125 ml/
min), WBC White blood cell (normal range: 4 ~ 10 × 109/L), RBC: Normal range:
men, 4.0 ~ 5.5 × 1012/L; women, 3.5 ~ 5.0 × 1012/L; Hb: normal range: men,
120-160 g/L; women, 110–150 g/L
*P < 0.05 vs. The HC
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20 (8–67) 88* (59–101) 27 (8–62) 9* (4–13) 21 (9–59) 12* (6–24) 24 (9–51) 18* (5–35)
WBC (×109/L) 9.8 (8.5–13.4) 7.9* (6.3–9.7) 9.7 (8.9–13.9) 17.7* (11.8–19.6) 9.6 (8.8–11.6) 13.1* (9.9–
16.2)
9.7 (8.6–13.2) 11.7* (9.6–13.7)
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1.7 (1.1–2.9) 0.8* (0.6–1.0) 1.7 (1.3–3.3) 0.3* (0.1–0.6) 1.9 (1.4–3.1) 0.7* (0.4–1.0) 1.7 (1.1–2.7) 0.7* (0.9–1.2)
RBC (×1012/L) 2.4 (2.1–2.7) 3.1* (2.6–3.3) 2.0 (1.7–2.5) 1.5* (1.3–2.0) 2.1 (1.9–3.1) 1.9* (1.7–2.3) 2.0 (1.9–2.9) 2.3* (2.0–2.8)














Data are expressed as median (range) or real case numbers
* P < 0.05 vs, before transplant rejection
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concentrations of IL-4 and IL-6 pre and post-transplant.
These data indicated that higher serum levels of Th17- and
Th1-type cytokines may be associated with renal trans-
plantation rejection.
The correlation of Tregs with Th17 cells in RTR patients
The potential relationship between the concentration of
serum inflammatory cytokines and the number of different
subsets of CD4+ T cells in RTR patients was analyzed
Fig. 1 FACS analysis of circulating CD4+ T cells. PBMCs from individual ESRF patients and HC subjects were stained with APC-anti-CD4, or PerCP-anti-CD4
and FITC-anti-CD25, or isotype controls, fixed and permeabilized, followed by intracellular staining with FITC-anti–IL-17 and PE-Cy7-anti-IFN-γ and
PE-anti-Foxp3. The frequency of CD4+, CD4+CD25+Foxp3+ Treg, CD4+IFN-γ−IL-17+ Th17, CD4+IFN-γ+IL-17− Th1 and CD4+IFN-γ+IL-17+ Th1/17 cells were
determined by flow cytometry analysis. The cells were gated on living lymphocytes and then gated on CD4+ cells, and at least about 30,000 events were
analyzed for each sample. The numbers of each type of CD4+ T cells were calculated, according to the total numbers of PBMCs, the frequency of total
CD4+, and different types of CD4+ T cells. a The representative charts of flow cytometry analysis. b-g Quantitative analysis. Data shown are representative
FACS charts or the mean numbers of each type of cells per ml of peripheral blood in individual subjects from two separate experiments. The horizontal
lines indicate the median values for each group
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(Fig. 4a-d). It was found that, the concentration of serum
IL-17 and IFN-γ was positively correlated with the number
of CD4+IFN-γ−IL-17+ Th17 and CD4+IFN-γ+IL-17− Th1
cells, respectively, in the four groups. Further analysis of
the relationship found a negative association between the
number of CD4+CD25+Foxp3+ T cells and the number of
CD4+IFN-γ−IL-17+ Th17 cells in the four groups.
These data suggested that different types of CD4+ T
cells may have variable functions during renal trans-
plantation rejection.
The relationship between the number of CD4+ T cells or
inflammatory cytokines and clinical parameters in TS
patients
To understand the importance of different subsets of CD4+
T cells and inflammatory cytokines, we analyzed the
potential association of the number of different types of
CD4+ T cells and inflammatory cytokines with clinical
parameters of the patients. It was found that the number of
CD4 +CD25 + Foxp3+ and CD4 + IFN-γ-IL-17+ Th17 cells
were positively correlated with the eGFR value and serum
Fig. 2 Stratification analysis of the numbers of different types of CD4+ T cells in different groups of renal transplant patients. The patients were
stratified into the transplant stable (TS) (13 cases), accelerated rejection (AMR) (8 cases), sub-acute rejection (AR) (7 cases) and chronic rejection
(CR) (7 cases) groups, the numbers of CD4+, CD4+CD25+Foxp3+ Treg, CD4+IFN-γ−IL-17+ Th17, CD4+IFN-γ+IL-17− Th1 and CD4+IFN-γ+IL-17+ Th1/17
cells and the ratios of Tregs to Th17 cells in these four groups of patients were analyzed. a The representative charts of flow cytometry analysis. b-g
Quantitative analysis. Data shown are representative FACS charts or the mean numbers of each type of cells per ml of peripheral blood in individual
subjects from two separate experiments. The horizontal lines indicate the median values for each group
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creatinine level, respectively, in the TS group (Fig. 5). Fur-
ther analysis revealed that the serum level of TNF-α and
IL-17 were positively correlated with serum creatinine level.
In contrast, the serum level of IL-10 was negatively corre-
lated with serum creatinine in the TS group. Moreover,
three groups of RTR also showed the same trend (data not
shown).
Discussion
Although renal transplantation provides a readily accessible
alternative strategy for patients with end-stage renal failure,
immune rejection remains a major hurdle to its implemen-
tation. In this study, we examined the pre and post-
transplantation number of different types of circulating
CD4+ T cells in ESRF patients. The study found that, the
number of CD4+IFN-γ−IL-17+ Th17, CD4+IFN-γ+IL-17−
Th1 and CD4+IFN-γ+IL-17+ Th1/17 cells in ESRF patients
were significantly increased compared to the HC, whereas
there was no significant difference in the number of CD4
+CD25+Foxp3+ T cells between patients and HC’s. Appar-
ently, there was an imbalance of Tregs to Th17 cells in
ESRF patients. Together these data suggested that dysregu-
lated CD4+ T cells play an important role in ESRF patients,
which were consistent with previous studies [36]. Moreover,
RTR showed increased number of CD4+IFN-γ−IL-17+
Th17, CD4+IFN-γ+IL-17− Th1 and CD4+IFN-γ+IL-17+
Fig. 3 The levels of serum inflammatory cytokines in ESRF and RTR patients. a The levels of serum IFN-γ, TNF-α, IL-2, IL-4, IL-6, IL-10 and IL-17 in
HCs and ESRF patients. b Plasma levels of serum IFN-γ, TNF-α, IL-2, IL-4, IL-6, IL-10 and IL-17 in patients at before and post-transplant in these
groups of patients were analyzed. The horizontal lines indicate the median values of the different groups
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Fig. 4 Correlation between the numbers of circulating CD4+ T cells and serum levels of inflammatory cytokines in RTR patients. Correlation
between the numbers of CD4+CD25+Foxp3+ T, CD4+IFN-γ−IL-17+ Th17 and CD4+IFN-γ+IL-17− Th1 cells and CD4+IFN-γ−IL-17+ Th17 cells, serum
levels of IL-17 and IFN-γ in TS (a), AMR (b), AR (c) and CR (d) patients
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Th1/17 cells and higher levels of serum IL-2, IFN-γ, TNF-α
and IL-17, but decreased number of CD4+CD25+Foxp3+ T
cells and lower levels of serum IL-10 compared to pre-
transplant and TS’s patients. Conceivably, an imbalance in
CD4+ T cells and inflammatory cytokines were new
target for immunotherapy for the intervention of renal
transplantation.
Increasing evidences have shown that multiple subsets of
effector CD4+ T cells play an important role in allograft re-
jection [37, 38]. In addition to direct killing activity by cyto-
toxic T lymphocytes, organ allotransplantation rejection
can occur through T-cell-mediated mechanisms, including
cytokine production, recruitment and activation of other
cytotoxic cells as well as B cells that produce xenoreactive
antibodies [39]. This study demonstrated that after renal
transplant, patients showed increased number of CD4+IFN-
γ+IL-17− Th1 cells and Th1-type cytokines (IL-2, IFN-γ,
TNF-α) compared to the pre-transplant and TS patients,
which was consistent with previous reports [40–42]. Simi-
larly, we detected significantly higher levels of cytokines in
post-transplant patients compared to pre-transplant. More-
over, the number of CD4+IFN-γ+IL-17− Th1 cells was posi-
tively correlated with the concentration of serum IFN-γ in
all the four post-transplant groups. However, there was no
significant difference in the Th2-type cytokines (IL-4, IL-6)
before and after transplant. These data suggested that Th1,
not Th2, likely play an important role in rejection, which
were consistent with Yuxin and coworkers [43]. The signifi-
cantly changed Th1 cells may stem from the inflammatory
environment, which preferably activate naive helper T cells
towards Th1 direction. In addition to Th1 cells, Th17 cells
expressing retinoic acid-related orphan receptor γt (RORγt)
that play a crucial role in the development of transplant
rejection by producing pro-inflammatory cytokine IL-17
[5–7]. Some studies have demonstrated that Th17 and IL-
17 contribute to rejection during heart, lung, liver and other
organ allotransplantation [8, 9]. Morever, similar studies
have also suggested that IL-17-secreting cell infiltration is a
prognostic marker for determining allograft outcome in
renal allograft biopsies with acute T-cell-mediated rejec-
tion (ATCMR) [44, 45]. However, the possible mecha-
nisms of Th17 and IL-17 in different types of renal
transplantation rejection remains unknown. Notably, we
detected significantly increased number of CD4+IFN-
γ−IL-17+ Th17 cells and Th17-type cytokines (IL-17) in
RTR compared to the pre-transplant status and TS pa-
tients. Moreover, the number of Th17 cells was positively
correlated with serum IL-17 concentration in the post-
transplant groups. These results suggested that Th17 cells,
as well as Th1 cells, play a key role in renal transplantation
Fig. 5 Correlation between the numbers of circulating CD4+ T cells or serum levels of inflammatory cytokines and disease activity in RTR patients.
Correlation between the numbers of CD4+CD25+Foxp3+ T, CD4+IFN-γ−IL-17+ Th17 cells and serum levels of TNF-α, IL-17 and IL-10 and the valves
of eGFR and the serum levels of Cr in TS patients
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rejection. More interestingly, the study found greater
number of CD4+IFN-γ+IL-17+ Th1/17 cells in RTR group
compared to pre-transplant and post-transplant TS pa-
tients. Previous studies have shown that CD4+IFN-γ−IL-17
+ Th17 cells are a rare population and the development of
these cells depends on the cytokine environment [46–48].
However, there was no significant correlation between the
number of Th1/17 cells and the clinical parameters. It is
possible that Th1/17 cells may not be potent effectors for
transplant rejection. Given that, following activation, T cells
can differentiate into different functional T cells, these Th1/
17 cells may be early differentiated and uncommitted cells.
We are interested to further investigating the role of Th1/
17 cells in the renal transplantation rejection.
Similar studies have reported that CD4+CD25+Foxp3+ T
cells play an important role in immune tolerance mechan-
ism during renal transplantation rejection [22–24]. A study
by Wen et al. [29] found that following transplantation,
RTR had significantly lower levels of CD4+CD25+Foxp3+ T
cells compared to ESRF and these cells had a positive linear
relationship with glomerular filtration rate. This finding
was consistent with our data that showed RTR had lower
number of CD4+CD25+Foxp3+ T cells compared to pre-
transplant status. This observation may partly reflect the
impact of immunosuppression on this cell population.
Studies of Tregs in RTR have shown variably changing
circulating levels during post-transplantation, suggesting
the possibility of regulatory cells production expressing
Foxp3 in immunosuppressed RTR’s.
Further studies on CD4+ T-cell subsets in RTR have
indicated that the number of CD4+CD25+Foxp3+ T cells
were negatively correlated with the number of CD4+IFN-
γ−IL-17+ Th17 cells, which was supported by molecular
studies showing the presence of reciprocal interaction be-
tween these subpopulation. Though, both Th17 and Tregs
require TGF-β1 during the early stage of differentiation, in
the presence of pro-inflammatory cytokines TGF-β1 and
IL-6, FoxP3 is down-regulated and T-cell with transitional
phenotype express a set of proteins essential for Th17
development [49]. Additionally, IL-2, which is required for
the regulation of Foxp3 expressing Tregs, has been found
to inhibit the development of Th17 cells [50]. Hence, it is
possible that the counteractive effects of IL-2 and IL-6 on
the differentiation of Th17 and Treg in the periphery may
hamper immunoregulatory responses and facilitate the
persistence of rejection. Morever, previous studies have
suggested that the FOXP3/IL-17 ratio may be a useful
indicator for representing the severity of tissue injury, allo-
graft dys-function and for predicting the clinical outcome
of ATCMR [44]. However, the precise roles of Treg and
Th17 cells in renal transplantation rejection need to be
further explored. Morever, our study showed that there
was no correlation between the number of CD4+CD25
+Foxp3+ T cells and the number of CD4+IFN-γ+IL-17−
Th1 cells, which was inconsistent with previous research
that showed suppression of Th1 cell-mediated responses by
Tregs through inhibition of monocyte-derived IL-6 [30].
This possibility could be attributed to the difference in the
internal circumstances of the patients. Previous studies
have reported that multiple inflammatory cytokines played
a key role in transplantation rejection response [31–33],
such as Th1-type (IL-2, IFN-γ, TNF-α) and Th17-type (IL-
17) cytokines. IL-2 is the critical mediator of acute rejection
whereas IFN-γ can mediate separate functions at the same
target organ during Graft-versus-host disease (GVHD)
[30–32]. TNF-α is a lymphocyte and macrophage derived
cytokine that is pleiotropic in its actions. Its proinflamma-
tory function suggest that it may play an important role in
initiating and orchestrating the rejection response. Studies
demonstrating a correlation in the expression of TNF-alpha
with the severity of the rejection episode have placed TNF-
alpha as a prime candidate marker of transplantation rejec-
tion [51, 52]. IL10 is a potent synthesis inhibitory factor
and anti-inflammatory, and is an important immunoregula-
tory component in the cytokine network of RTR’s [53]. IL-
17 can induce the expression of proinflammatory TNF-α,
and MCP-1 and MIP-1 to promote tissue inflammation
[33]. In the present study, we found that RTR patients
displayed higher levels of serum IL-2, IFN-γ, TNF-α and
IL-17, but not IL-4 and IL-6, whereas TS patients displayed
higher levels of serum IL-10 compared to pre-transplant
status. More importantly, the serum levels of TNF-α and
IL-17 were positively correlated with the concentrations of
serum Cr, whereas IL-10 level was negatively correlated
with the concentration of serum Cr in all the four post-
transplant groups. These data indicated that an imbalance
of serum Th1- and Th17-type cytokines may be a positive
regulator during renal transplantation rejection process.
Conceivably, the change in inflammatory cytokines may be
a new target for designing immunotherapy for the interven-
tion of renal transplantation rejection response.
Conclusion
In summary, our data showed a significantly increased
number of circulating Th1 and Th17 cells as well as
higher levels of serum inflammatory cytokines in ESRF
patients. RTR displayed lower number of Tregs, Treg to
Th17 cells ratio and serum IL-10, and higher numbers
of Th1 and Th17 and related cytokines compared to the
pre-transplant and post-transplant TS patients. These
novel finding suggested that effector CD4+ T cells may
be controlled by Tregs during renal transplantation
rejection and the imbalance of Treg/Th17 axis may be
associated with the process of renal transplantation
rejection. The limitations of this study include small
sample size and lack of functional studies of different
types of CD4+ T cells. Thus, further studies in larger
population are warranted.
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